2 results match your criteria: "Virgina G Piper Cancer Center[Affiliation]"
Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy.
J Natl Cancer Inst
March 2014
Affiliations of authors: Taussig Cancer Institute and Lerner College of Medicine (DPSS, AAK) and Digestive Disease Institute and Lerner College of Medicine (RMW), Cleveland Clinic, Cleveland, OH; Virgina G. Piper Cancer Center, Translational Genomics Research Institute, Scottsdale, AZ (RKR).
Pancreatic adenocarcinoma, even when resectable, remains highly lethal. Although surgical outcomes have improved considerably, median overall survival after surgery and adjuvant therapy such as single-agent gemcitabine remains less than 2 years. We discuss preclinical and clinical data supporting the contention that even early-stage pancreatic cancer is a systemic disease.
View Article and Find Full Text PDFA randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination.
Cancer Chemother Pharmacol
March 2011
Virgina G Piper Cancer Center, TGen, Scottsdale, AZ, 85259, USA.
Purpose: This study evaluated PX-12, a novel small molecule inhibitor of the proto-oncogene (Trx-1), in patients with previously treated advanced pancreatic cancer (APC).
Methods: PX-12 (54 or 128 mg/m²) was administered by 3-hour IV infusion daily × 5 days every 21 days (n = 17). Patients were randomized to either 54 or 128 mg/m² and then stratified based on CA 19-9 level (≥ 1,000 vs.